Weekly events giving members the opportunity to meet with journalists online and pitch their story ideas.

“I haven’t enjoyed getting a pitch this much in, well…ever!” — Ben Gruber, Reuters


A Conversation with Qualcomm Tricorder XPrize Innovators

Winning Star Trek Tricorder Device to Be Presented to Experts at the 69th AACC Annual Scientific Meeting

Monday, Jul 31, 2017, 7:30pm - 9:00pm EDT


Jessica Ching, MBA
Lead Advising Consultant, Life Sciences, XPRIZE
Eugene Chan, MD
Chief Executive Officer and Head Scientist, DNA Medicine Institute (DMI)
Chung-Kang Peng, PhD
Leader, Dynamical Biomarkers Group
Co-Director, Rey Institute for Nonlinear Dynamics in Medicine, Beth Israel Deaconess Medical Center
Philip Charron
Final Frontier Medical Devices
Executive Board Member, Basil Leaf Technologies

The Qualcomm Tricorder XPrize competition challenged research teams to develop a device inspired by the fictional Star Trek tricorder that weighs no more than five pounds and diagnoses 13 health conditions and captures five real-time health vital signs. Devices were judged for their diagnostic accuracy and user experience.

In this session, a member of the winning team, Final Frontier Medical Devices, will present for the first time the real-life tricorder DxtER to researchers at a U.S. scientific conference. The audience will hear from contest finalist Dynamical Biomarkers Group and semi-finalist DMI as well. The speakers will discuss the technology they have developed and its potential future, while also sharing the inspiration for their devices and the hurdles they encountered.

This is an opportunity to hear more from these innovators about the drivers and status of the digital health revolution, as well as the breakthroughs needed for this area of science fiction to become reality. These include the emergence of precision diagnostics that utilize novel sensing technologies with advanced technological integration, and that will require new regulatory pathways and healthcare industry acceptance.

Following the presentation, there will be a moderator-led Q&A session featuring questions from the audience, who are experts in the field with the knowledge and experience needed to assess the science of DxtER as well as its impact on patient care.

Registration is closed for this event.

For more information or questions, please email:

[email protected]